Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM)
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Extended-release naltrexone (XR-NTX, VIVITROL) is an FDA-approved medication with efficacy in
treating alcohol dependence and prevention of relapse to opioid dependence. It has shown
promise in reducing relapse to amphetamine use among amphetamine-dependent, yet currently
amphetamine-abstinent heterosexuals. The investigators will expand upon this promising work
to determine whether monthly intramuscular injections of naltrexone will reduce
methamphetamine (meth) use among actively using, meth-dependent men who have sex with men
(MSM) in this double-blind randomized controlled trial of extended-release naltrexone versus
placebo. The investigators will focus on MSM because of the disproportionate and intertwining
epidemics of meth use and HIV in this population.
Phase:
Phase 2
Details
Lead Sponsor:
San Francisco Department of Public Health
Collaborators:
Alkermes, Inc. National Institute on Drug Abuse (NIDA)